The Korean government has introduced new support measures for biotech and pharmaceutical ventures, including an AI-enabled joint R&D program designed to strengthen collaboration between AI companies and pharmaceutical firms.
With its AI-powered drug discovery platform and predictive modeling technologies, Calici is well positioned to benefit from these initiatives. Expanded support for R&D and technology commercialization is expected to contribute to the company’s continued growth and innovation.
Industry experts anticipate that Calici will further expand its role in collaborative research and technology transfer partnerships as open innovation across the pharmaceutical sector continues to grow.